A Study to Evaluate Effects of KN056 in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-07-08
Target enrollment:
Participant gender:
Summary
This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to
investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the
immune response of KN056 in healthy participants.